Overall market sentiment has been high on Odonate Therapeutics Inc (ODT) stock lately. ODT receives a Bullish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With ODT Stock Today?
Odonate Therapeutics Inc (ODT) stock is trading at $3.74 as of 9:55 AM on Wednesday, Apr 7, an increase of $0.28, or 8.09% from the previous closing price of $3.46. The stock has traded between $3.36 and $3.78 so far today. Volume today is below average. So far 255,431 shares have traded compared to average volume of 2,483,213 shares.
To see the top 5 stocks in the Biotechnology industry click here.
More About Odonate Therapeutics Inc
Odonate Therapeutics Inc is a US-based pharmaceutical company that is engaged in the development of therapeutics which improves and extends the lives of patients with cancer. The company mainly focuses on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs, taxanes, which are widely used in the treatment of cancer including breast cancer. The key product of the company is Tesetaxel which is chemotherapy for oral administration with a low pill burden for various types of cancers.
Click Here to get the full Stock Score Report on Odonate Therapeutics Inc (ODT) Stock.
